Literature DB >> 32813188

Does healthcare regime affiliation influence the clinical outcomes of patients with rheumatoid arthritis?

Julián E Barahona-Correa1,2, Jorge Flórez-Suárez2, Paola Coral-Alvarado2,3, Paul Méndez-Patarroyo2,3, Gerardo Quintana-López4,5,6,7.   

Abstract

BACKGROUND/
PURPOSE: Adequate control of disease activity in rheumatoid arthritis (RA) depends, to a great extent, on the access to a rheumatologist. This study aimed to compare the disease outcomes of patients with RA, based on their healthcare regime affiliation.
METHODS: A retrospective observational study of Colombian patients with RA in three outpatient services of different regimes: Contributory (CR, workers and their families with a monthly income above a yearly defined threshold, approximately US$ 220, who allocate a percentage of their income to financing the national health fund and to get access to healthcare services), subsidized (SR, a vulnerable population with a monthly income below the threshold, who have access to healthcare through the national health fund; comparable to the USA Medicaid population), and an excellence clinical care center (C3, access to specialized care, regardless of their healthcare affiliation regime). Data were collected from clinical records for 2 years of follow-up and included demographics, lag times between appointments, and time in high disease activity. We used the Mantel-Cox test for the analysis of time to remission/low disease activity.
RESULTS: A total of 240 patients were included (80 patients per regime). At the start of follow-up, mean age was 53.7 years; 21.6% of patients were men; 79.6% of patients had established RA; 72.9% of patients had high disease activity. Patients in the CR had longer lag times between scheduled appointments (p < 0.0001). During follow-up, SR had the highest proportion of patients with high disease activity. Survival curve analysis showed no significant difference between SR and CR groups (p = 0.2903), but was significantly different compared with the C3 group (p < 0.0001). Median survival in high disease activity was greater in the SR group (293 days), followed by CR (254 days), and finally by C3 (64 days).
CONCLUSION: Patients that were treated in the excellence clinical care center had better outcomes when compared with other regimes. These data support that healthcare regime may influence disease outcome in patients with RA. Key Points • Prompt access to healthcare in patients with rheumatoid arthritis is pivotal for an adequate control of the disease, for timely adjustment of treatment, and to reduce both the societal burden of the disease and its impact on individual well-being. • As an example of "structural iatrogenesis," healthcare regime affiliation appears to influence disease outcomes in patients with rheumatoid arthritis, in whom differences between regimes are observed. The most vulnerable patients appear to experience the worst outcomes. • Excellence clinical care centers for patients with rheumatoid arthritis should be implemented as an alternative to counteract structural healthcare barriers and as an approach to improve clinical outcomes through a tighter disease control.

Entities:  

Keywords:  Healthcare disparities; Insurance; Latin America; Rheumatoid arthritis; Rheumatology

Mesh:

Year:  2020        PMID: 32813188     DOI: 10.1007/s10067-020-05347-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  19 in total

1.  A Consensus Position Paper From REAL-PANLAR Group About the Methodological Approach for the Accreditation Process of Centers of Excellence in Rheumatoid Arthritis in Latin America.

Authors:  Pedro Santos-Moreno; Carlo V Caballero-Uribe; Mario H Cardiel; Claudio Galarza-Maldonado; Loreto Massardo; Carlos Pineda; Enrique Soriano; Carlos Alberto Castro; Laura Villarreal; Diana Buitrago
Journal:  J Clin Rheumatol       Date:  2019-01       Impact factor: 3.517

2.  Long-term outcomes of treat-to-target strategy in established rheumatoid arthritis: a daily practice prospective cohort study.

Authors:  Nicole Pamplona Bueno de Andrade; Rafael Mendonça da Silva Chakr; Ricardo Machado Xavier; Daniela Viecceli; Ricardo Henrique Bilycz Correa; Cilomar Martins de Oliveira Filho; Claiton Viegas Brenol
Journal:  Rheumatol Int       Date:  2017-03-14       Impact factor: 2.631

3.  Gastric cancer survival and affiliation to health insurance in a middle-income setting.

Authors:  Esther de Vries; Claudia Uribe; Constanza Pardo; Valery Lemmens; Ellen Van de Poel; David Forman
Journal:  Cancer Epidemiol       Date:  2014-11-26       Impact factor: 2.984

4.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

5.  Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.

Authors:  Mark C Genovese; Joan M Bathon; Richard W Martin; Roy M Fleischmann; John R Tesser; Michael H Schiff; Edward C Keystone; Mary Chester Wasko; Larry W Moreland; Arthur L Weaver; Joseph Markenson; Grant W Cannon; George Spencer-Green; Barbara K Finck
Journal:  Arthritis Rheum       Date:  2002-06

Review 6.  Rheumatoid arthritis.

Authors:  Josef S Smolen; Daniel Aletaha; Anne Barton; Gerd R Burmester; Paul Emery; Gary S Firestein; Arthur Kavanaugh; Iain B McInnes; Daniel H Solomon; Vibeke Strand; Kazuhiko Yamamoto
Journal:  Nat Rev Dis Primers       Date:  2018-02-08       Impact factor: 52.329

Review 7.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Authors:  Josef S Smolen; Robert Landewé; Johannes Bijlsma; Gerd Burmester; Katerina Chatzidionysiou; Maxime Dougados; Jackie Nam; Sofia Ramiro; Marieke Voshaar; Ronald van Vollenhoven; Daniel Aletaha; Martin Aringer; Maarten Boers; Chris D Buckley; Frank Buttgereit; Vivian Bykerk; Mario Cardiel; Bernard Combe; Maurizio Cutolo; Yvonne van Eijk-Hustings; Paul Emery; Axel Finckh; Cem Gabay; Juan Gomez-Reino; Laure Gossec; Jacques-Eric Gottenberg; Johanna M W Hazes; Tom Huizinga; Meghna Jani; Dmitry Karateev; Marios Kouloumas; Tore Kvien; Zhanguo Li; Xavier Mariette; Iain McInnes; Eduardo Mysler; Peter Nash; Karel Pavelka; Gyula Poór; Christophe Richez; Piet van Riel; Andrea Rubbert-Roth; Kenneth Saag; Jose da Silva; Tanja Stamm; Tsutomu Takeuchi; René Westhovens; Maarten de Wit; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2017-03-06       Impact factor: 19.103

8.  Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study.

Authors:  G Jones; A Sebba; J Gu; M B Lowenstein; A Calvo; J J Gomez-Reino; D A Siri; M Tomsic; E Alecock; T Woodworth; M C Genovese
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

9.  Time-averaged disease activity fits better joint destruction in rheumatoid arthritis.

Authors:  Hideaki Tsuji; Koichiro Yano; Moritoshi Furu; Noriyuki Yamakawa; Katsunori Ikari; Motomu Hashimoto; Hiromu Ito; Takao Fujii; Wataru Yamamoto; Koichiro Ohmura; Atsuo Taniguchi; Shigeki Momohara; Fumihiko Matsuda; Cornelia F Allaart; Hisashi Yamanaka; Tsuneyo Mimori; Chikashi Terao
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

10.  Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice.

Authors:  G A Versteeg; L M M Steunebrink; H E Vonkeman; P M Ten Klooster; A E van der Bijl; M A F J van de Laar
Journal:  Clin Rheumatol       Date:  2018-02-01       Impact factor: 2.980

View more
  1 in total

1.  Incident Rheumatoid Arthritis Following Statin Use: From the View of a National Cohort Study in Korea.

Authors:  Mi Jung Kwon; Joo-Hee Kim; Ji Hee Kim; Hye-Rim Park; Nan Young Kim; Sangkyoon Hong; Hyo Geun Choi
Journal:  J Pers Med       Date:  2022-04-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.